Skip to main content
Search

GnRH agonist use for fertility preservation despite gonadotoxic chemotherapy

Published on September 26, 2019   66 min

Other Talks in the Series: The Female Reproductive System: from Basic Science to Fertility Treatments

Please wait while the transcript is being prepared...
0:00
Hello everybody. My name is Zeev Blumenfeld. I'm Associate Professor at the Technion Faculty of Medicine in Haifa, Israel. I'm going to talk to you about the "GNRH Agonist Use for Fertility Preservation Despite Gonadotoxic Chemotherapy".
0:18
The next slide shows the main three avenues of fertility preservation. The first of them, which is clinically accepted and no argument about it, is using ART/IVF with freezing of embryos or unfertilized ova. The second one is ovarian cryopreservation with either whole ovary autotransplantation, ovarian slices autotransplantation, xenotransplantation of nude mice, and thawing and I.V.M. However, this is still investigational. The third avenue, the one I'm going to elaborate on, is to decrease or arrest follicular loss by GnRH agonist adjuvant co-treatment.
1:10
Next slide shows that the first avenue of IVF and cryopreservation of embryo or ova is efficient, it's clinically available. However, it may be possibly dangerous in estrogen aggravated situations and diseases such as breast cancer and systemic lupus erythematosus. The second avenue for ovarian cryopreservation and autotransplantation, the potential is very high. It has been shown to be effective in sheep, mice, and human. Up to now, over 130 newborns worldwide have been reported. However, it's still investigational. It main induce ovarian antibodies, and most importantly, there is a risk of cancer cellular institution mainly in leukemia.
Show
Hide

GnRH agonist use for fertility preservation despite gonadotoxic chemotherapy

Embed in course/own notes